New Issue: Moody's assigns Aa1 to University of Washington's Series 2015 Lease Rev. Bds; outlook stable

$2.3B rated debt

UNIVERSITY OF WASHINGTON, WA
Public Colleges & Universities
WA

Moody's Rating

<table>
<thead>
<tr>
<th>ISSUE</th>
<th>RATING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lease Revenue Bonds, Series 2015A</td>
<td>Aa1</td>
</tr>
<tr>
<td>Sale Amount</td>
<td>$104,565,000</td>
</tr>
<tr>
<td>Expected Sale Date</td>
<td>09/24/15</td>
</tr>
<tr>
<td>Rating Description</td>
<td>Lease Rental: Other</td>
</tr>
<tr>
<td>Lease Revenue Bonds, Series 2015B (Taxable)</td>
<td>Aa1</td>
</tr>
<tr>
<td>Sale Amount</td>
<td>$24,455,000</td>
</tr>
<tr>
<td>Expected Sale Date</td>
<td>09/24/15</td>
</tr>
<tr>
<td>Rating Description</td>
<td>Lease Rental: Other</td>
</tr>
</tbody>
</table>

Moody's Outlook  STA

NEW YORK, September 15, 2015 --Moody's Investors Service assigns a Aa1 rating to University of Washington's (UW) $104.6 million of Lease Revenue Bonds, Series 2015A (maturing 2048) and $24.5 million of Lease Revenue Bonds, Series 2015B (Taxable) (maturing as a bullet maturity in 2018). The bonds are issued by Washington Biomedical Research Properties (WBRP 3.2). The outlook is stable.

SUMMARY RATING RATIONALE

The Aa1 rating on the Lease Revenue bonds is one level below the Aaa rating on the University of Washington's (UW) Aaa General Revenue Bond rating, reflecting a lease structure for the transaction with no abatement risk, including a ground lease for privately-owned property and a facilities lease with a sole purpose corporation.

The University of Washington's highest Aaa rating reflects the synergies and strengths of its large-scale research, healthcare and educational operations and revenues. UW is one of the nation's largest research enterprises and one of the two largest healthcare providers in the Seattle region (and the only academic medical center in a five-state region) with generally balanced operating performance and well-diversified revenue streams.

Offsetting challenges are growing healthcare operations with narrower margins, high reliance on federal research funding and rising debt levels.

OUTLOOK

UW's stable outlook reflects expectations of a strong market position supported by its large national research profile, strong student demand and regional health care presence as well as good gift revenue, manageable near-term borrowing plans and operational flexibility to cope with constrained federal research funding. It also incorporates expectations of growing balance sheet resources that will provide a growing cushion for debt and operations.

WHAT COULD MAKE THE RATING GO UP
WHAT COULD MAKE THE RATING GO DOWN

-Growth in balance sheet resources lower than Aaa-rated peers, resulting in relatively weaker balance sheet metrics
-Material debt plans beyond those outlined
-Significant reduction in research funding and revenue
-Sustained deterioration in university or medical center operations and cash flow

STRENGTHS

-Significant national research profile, good student demand, major clinical care provider for the Pacific Northwest
-Integrated planning, active debt and project management, and very good disclosure
-Good financial flexibility, with $1.6 billion of unrestricted financial resources
-Consistently favorable operations, with a 10.5% operating cash flow margin for FY 2014

CHALLENGES

-Increasing leverage, debt issuance outpacing growth of financial resources and revenues
-Slowing growth in net tuition revenues, with the state re-assuming full tuition-setting authority for in-state undergraduate tuition
-Increasingly competitive research funding environment
-Significant healthcare exposure with lower margins and liquidity

RECENT DEVELOPMENTS

Recent developments are included in DETAILED RATING RATIONALE.

DETAILED RATING RATIONALE

MARKET POSITION: LEADING NATIONAL RESEARCH PROFILE AND STATE’S FLAGSHIP PUBLIC UNIVERSITY

University of Washington (UW) will maintain its strong market position, anchored by its large, national research enterprise and good student demand as the state’s flagship university. UW is a leading research enterprise, with a substantial $1.3 billion in research awards in FY 2015. While the research environment is increasingly competitive, UW is well positioned given the scale, diversity, and reputation of its research program. Further, UW has contingency plans to cope with grant reductions and has operating flexibility from its largely variable expense structure.

Student demand will remain healthy, based on the university’s academic reputation and diversified undergraduate and graduate programs. Total enrollment has grown by over 9.5% in the last five years. While growth in net tuition revenue has been favorable in recent years due to this enrollment growth and tuition increases, we expect net tuition revenue to moderate over the next several years. The state has re-assumed in-state undergraduate tuition setting authority, and is requiring a 15% decrease in resident undergraduate tuition over the next two years. Increases in state funding will offset this move in the short term, but loss of tuition setting flexibility is a credit negative in the longer term. A partial mitigant is UW’s diverse enrollment, with about 30% of incoming freshmen are non-resident and one-third of total enrollment at the graduate and professional level.

Growing healthcare enterprise

UW’s significant healthcare enterprise is a key strategic focus tied to research and medical education. With a breadth of services, active management, and university board attention to enterprise risk, we anticipate that healthcare activities will continue to generate positive cash flow and remain a credit additive.
Patient care is substantial with $1.2 billion or 27% of FY 2014 UW's revenues (up to $2.0 billion or 38% when including Northwest Hospital and Valley Medical Center, both components units). The 450-bed University of Washington Medical Center (UWMC) is the flagship facility and an operating division of the university. UW Medicine's service area is substantial as the only academic health system and Level 1 trauma care provider for Washington, Wyoming, Alaska, Montana and Idaho (WWAMI). UW's School of Medicine is also the only public medical school for the region, with over 4,700 clinical faculty.

UW's board invested in the healthcare operations through capital investment and strategic alliances. UW shares ownership of the Seattle Cancer Care Alliance (A2 positive) with Fred Hutchinson Cancer Research Center (A3 stable) and Seattle Children's Healthcare System (Aa2 stable). It is one of two preferred partners for The Boeing Company, one of two Accountable Care Programs for state employees in a five county area beginning January 2016 and the preferred complex tertiary/quaternary health system for PeaceHealth hospitals (not rated).

OPERATING PERFORMANCE, BALANCE SHEET, AND CAPITAL PLANS: GOOD CASH FLOW FROM DIVERSIFIED REVENUE STREAMS; RESOURCES PROVIDE GOOD FINANCIAL FLEXIBILITY; LEVERAGE INCREASING

UW will continue to produce good operating cash flow, in the 10-12% range, from its diverse revenues, reflecting strong fiscal oversight offsetting thin-margined research and healthcare operations and low tuition increases. Expense pressures come from higher pension costs and non-capitalized capital expenses.

UW projects FY 2015 to be at least comparable to FY 2014 with improved margins at UW Medicine. UW Medicine exceeded budgeted performance in FY 2015 with strong performance at UWMC, with good demand expected to continue following the opening of significant components of UWMC’s tower expansion this year (final completion of the project is expected in October 2017).

The State of Washington (rated Aa1, stable) provides only 6% of Moody's-calculated operating revenue. State funding increased nearly 20% to $292 million for the current FY 2016-2017 biennium, with the increase largely offsetting the tuition reduction. The increase also provided for general wage increases and for STEM and healthcare education funds. However, pressure on the state budget may arise as the state looks to fully fund K-12 education costs as compelled under the Supreme Court of Washington's "McCleary" ruling.

The University of Washington's financial assets provide excellent flexibility, with $4.9 billion of total financial resources at the end of FY 2014, $1.6 billion of which was unrestricted. Total financial resources have grown by nearly 50% over the past five years, and are expected to increase further based on cash flow and fundraising.

Although currently not in an active comprehensive campaign, UW continues to generate strong gift flow, averaging $180 million annually over the three years ended June 30, 2014. The university reports another strong year for FY 2015. UW is in the early stages of a comprehensive campaign, with a tentative $4.0 billion goal.

Capital spending has been high as the university has invested in student housing among other initiatives, with over $2.4 billion invested in plant from FY 2010-2014. While the university has benefitted from a mix of funding sources, outstanding debt has increased substantially over this same time frame, from a comparatively low $1.2 billion in FY 2010 to over $2.5 billion on a pro-forma basis. Pro-forma debt includes the Series 2015 Lease Revenue Bonds, the recently issued Series 2015 C/D GRBs, and assumes full issuance of $250 million of Commercial Paper.

While this debt level currently remains manageable, with maximum debt service consuming less than 5% of operations, UW's leverage metrics are now at the lower end of the Aaa-rating category. Debt issuance is expected to moderate, with management projecting to issue about $70 million in new debt through FY 2018 for campus projects. This would more than be offset by principal repayments. However, material issuance above the current plans given the increase in leverage over the past five years could result in rating or outlook pressure.

Liquidity

UW holds $1.6 billion in operating funds, largely cash and treasuries/agencies. FY 2014 unrestricted monthly liquidity of $1.6 billion translated to 146 days, lower than other Aaa-rated institutions, in part reflecting the large research base funded by reimbursable research grants and expanding healthcare operations normally with lower liquidity. Liquidity is projected to be higher for June 30, 2015.

At June 30, 2015, UW's Consolidated Endowment Fund (CEF) increased to $3.1 billion from $2.8 billion at June 30, 2014 and reported a 6.8% twelve-month investment return, well above peer institutions. The portfolio allocations are generally consistent with other large endowment portfolios. UW Investments Office is appropriately
staffed for the complexity of the endowment, with over 20 investment and operational professionals, and additional oversight and expertise provided by investment advisory committee members and external investment professionals. On September 10, 2015, UW's board announced the formation of University of Washington Investment Management Company (UWIMCO), which will oversee the CEF.

DEBT STRUCTURE AND LEGAL COVENANTS

Debt Structure

All of UW's long term debt is fixed rate. The university does use its $250 million commercial paper program as an interim financing vehicle, introducing some variable rate exposure but with de minimis risk given the good liquidity and only modest budget exposure.

Debt-Related Derivatives

None

Pensions and OPEB

UW has significant pension and benefit costs which represent a credit challenge. The university expensed a total of $467 million for pension and healthcare benefits, $179 million and $288 million respectively, for FY 2014. This amounts to a very substantial 11% of operating expenses. However, most of the payment for healthcare benefits was for current employees, with UW paying only a $150 subsidy per retiree.

UW offers two contributory pension plans - the Washington State Public Employees Retirement System ("PERS") plan, a defined-benefit retirement plan with three levels, and the University of Washington Retirement Plan ("UWRP"), a defined-contribution plan. The University of Washington Supplemental Retirement Plan, a defined-benefit plan, is closed to employees who were not active participants on February 28, 2011. UW contributes to PERS, a cost-sharing, multiple-employer, defined-benefit pension plan administered by the State Department of Retirement Systems ("DRS"). For FY 2016, UW's contribution is 11.18% of payroll.

For June 30, 2014 PERS Plan 1 has a participating employers' net pension liability of $5.04 billion, representing 61% funding. PERS Plan 2 and Plan 3, with a defined contribution plan, have a participating employers' net pension liability of $2.02 billion with over 90% funding. UW projects it will report a $830 million decrease in its Fiscal Year 2015 Beginning Unrestricted Net Position due to the implementation of GASB 68, which includes approximately $250 million for Harborview, a related party owned by King County and excluded from UW's financial results. However, as all of the Harborview employees are university employees, UW is required to include the Harborview employees in the related pension liability in its financial results.

UW employees are provided OPEB retirement benefits through the Washington State Health Care Authority. Premiums are calculated on a pay-as-you-go basis. UW is only required to pay a $150 subsidy for each retiree.

GOVERNANCE AND MANAGEMENT: ACTIVE CENTRAL GOVERNANCE AND MANAGEMENT, WITH STRONG BUDGETING AND FINANCIAL OVERSIGHT

University of Washington's governance and management are excellent, contributing to its Aaa rating. The Board of Regents is comprised of 10 members, including one student, and includes leaders of major corporations located in the state. The board thoroughly reviews all capital projects and planned borrowings to finance the projects, both through debt issuance or borrowing from UW's internal bank, including financial review of projects' revenue sources for debt service repayment and project staging, checkpoints and "off ramps". Capital projects are integrated into and centrally managed in UW's "One Capital Plan", its comprehensive 10-year strategic plan.

UW provides excellent bondholder disclosure that is posted to both EMMA and its own website. The university has external audits done for its separate organizations, including the healthcare organizations, the General Revenues fund and the internal lending bank.

KEY INDICATORS (FY 2014 financial data, fall 2014 enrollment data)

- Full-Time Equivalent Enrollment: 54,857 students
- Total Financial Resources: $4.9 billion
- Total Cash & Investments: $4.8 billion
-Total Pro-Forma Direct Debt: $2.5 billion
-Total Operating Revenue: $4.4 billion
-Reliance on Grants and Contract Revenue (% of Moody's Adjusted Operating Revenue): 29%
-Reliance on Patient Care Revenue (% of Moody's Adjusted Operating Revenue): 27%
-Reliance on Tuition & Auxiliaries Revenue (% of Moody's Adjusted Operating Revenue): 23%
-Monthly Days Cash on Hand: 146 days
-Operating Cash Flow Margin: 10.5%
-Three-Year Average Debt Service Coverage: 3.6 times
-State of Washington Rating: Aa1, stable outlook

OBLIGOR PROFILE
Founded in 1861, University of Washington is the state's flagship university with more than 50,000 FTE students on its campuses in Seattle, Tacoma and Bothell. UW's operations are sizable with $4.4 billion of operating revenues. UW is also one of the nation's largest research universities with $1.3 billion of research awards for fiscal year 2015. The university operates UW Medicine, with nearly $2 billion of revenues and includes University of Washington Medical Center.

LEGAL SECURITY
The Series 2015A and B Lease Revenue Bonds (for WBRP 3.2) are secured by lease payments made by University of Washington solely from its General Revenues, under a facilities lease between UW and WBRP 3.2. UW's obligation to pay the lease payments is on parity with the other Aa1-rated lease revenue bonds - the Series 2005E, 2006J and Series 2014 bonds (for WBRP II), the Series 2013 bonds (for WBRP I) and the Series 2010B (for WBRP 3.1). General Revenues include all non-appropriated and non-restricted revenues and fund balances, with $2.64 billion of pledged general revenues and $1.6 billion of general revenue balances for FY 2014. The General Revenues are also pledged for UW's General Revenue Bonds (rated Aaa), General Revenue Notes (rated P-1) and for the lease payments for the TSB Lease Property Revenue Bonds (rated Aa2). Lease payments are not subject to appropriation or abatement. There is no debt service reserve fund for any bond series.

The borrower, WBRP 3.2, is a single purpose not-for-profit corporation related by management to the National Development Council. The Council creates sole purpose subsidiaries that enter into financing leases with UW for individual projects. Given that each subsidiary is a sole-purpose entity with no operating risk, the lessor is deemed to be bankruptcy remote.

For the Series 2015 bonds, WBRP 3.2 entered into a ground lease with City Investors XII LLC, the property owner on July 30, 2010 that was extended as of September 30, 2015 and terminates May 31, 2063. The Ground Lessor has the right to terminate the ground lease if construction has not commenced by early- to mid-2019. WBRP entered into a facility lease with UW for the new biomedical research building also terminating May 31, 2063 subject to a 5-year extension. The university is obligated under the facilities lease to begin paying base rent and a lump sum payment on March 1, 2018. WBRP assigned its interest in the lease to the Trustee, including UW's lease payments. At the end of the lease term, the property reverts to City Investors XII, the property owner. There is no debt service reserve fund.

For information on the legal security for UW's other rated debt, see Moody's report dated September 2, 2015.

USE OF PROCEEDS
Proceeds of the Series 2015 Lease Revenue Bonds will fund the costs of construction and furnishing a biomedical research facility in South Lake Union, pay capitalized interest, and pay issuance costs. The project is the second part of the third phase of a multi-phase development of a campus of biomedical research facilities leased by UW's School of Medicine.

RATING METHODOLOGIES
The principal methodology used in this rating was U.S. Not-for-Profit Private and Public Higher Education
published in August 2011. An additional methodology used in this rating was The Fundamentals of Credit Analysis for Lease-Backed Municipal Obligations published in December 2011. Please see the Credit Policy page on www.moodys.com for a copy of these methodologies.

REGULATORY DISCLOSURES

For ratings issued on a program, series or category/class of debt, this announcement provides certain regulatory disclosures in relation to each rating of a subsequently issued bond or note of the same series or category/class of debt or pursuant to a program for which the ratings are derived exclusively from existing ratings in accordance with Moody’s rating practices. For ratings issued on a support provider, this announcement provides certain regulatory disclosures in relation to the rating action on the support provider and in relation to each particular rating action for securities that derive their credit ratings from the support provider’s credit rating. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating. For further information please see the ratings tab on the issuer/entity page for the respective issuer on www.moodys.com.

Regulatory disclosures contained in this press release apply to the credit rating and, if applicable, the related rating outlook or rating review.

Please see www.moodys.com for any updates on changes to the lead rating analyst and to the Moody’s legal entity that has issued the rating.

Please see the ratings tab on the issuer/entity page on www.moodys.com for additional regulatory disclosures for each credit rating.

Analysts

Diane F. Viacava
Lead Analyst
Public Finance Group
Moody’s Investors Service

Susan Fitzgerald
Additional Contact
Public Finance Group
Moody’s Investors Service

Contacts

Journalists: (212) 553-0376
Research Clients: (212) 553-1653

Moody’s Investors Service, Inc.
250 Greenwich Street
New York, NY 10007
USA

© 2015 Moody’s Corporation, Moody’s Investors Service, Inc., Moody’s Analytics, Inc. and/or their licensors and affiliates (collectively, “MOODY’S”). All rights reserved.

CREDIT RATINGS ISSUED BY MOODY’S INVESTORS SERVICE, INC. AND ITS RATINGS AFFILIATES (“MIS”) ARE MOODY’S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND CREDIT RATINGS AND RESEARCH PUBLICATIONS PUBLISHED BY MOODY’S (“MOODY’S PUBLICATIONS”) MAY INCLUDE MOODY’S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES. MOODY’S DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY
MAY NOT MEET ITS CONTRACTUAL, FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS AND MOODY'S OPINIONS INCLUDED IN MOODY'S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. MOODY'S PUBLICATIONS MAY ALSO INCLUDE QUANTITATIVE MODEL-BASED ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY'S ANALYTICS, INC. CREDIT RATINGS AND MOODY'S PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND CREDIT RATINGS AND MOODY'S PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. NEITHER CREDIT RATINGS NOR MOODY'S PUBLICATIONS COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY'S ISSUES ITS CREDIT RATINGS AND PUBLISHERS MOODY'S PUBLICATIONS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.

MOODY'S CREDIT RATINGS AND MOODY'S PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS FOR RETAIL INVESTORS TO CONSIDER MOODY'S CREDIT RATINGS OR MOODY'S PUBLICATIONS IN MAKING ANY INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT MOODY'S PRIOR WRITTEN CONSENT.

All information contained herein is obtained by MOODY’S from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided “AS IS” without warranty of any kind. MOODY’S adopts all necessary measures so that the information it uses in assigning a credit rating is of sufficient quality and from sources MOODY’S considers to be reliable including, when appropriate, independent third-party sources. However, MOODY’S is not an auditor and cannot in every instance independently verify or validate information received in the rating process or in preparing the Moody’s Publications.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability to any person or entity for any indirect, special, consequential, or incidental losses or damages whatsoever arising from or in connection with the information contained herein or the use of or inability to use any such information, even if MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is advised in advance of the possibility of such losses or damages, including but not limited to: (a) any loss of present or prospective profits or (b) any loss or damage arising where the relevant financial instrument is not the subject of a particular credit rating assigned by MOODY’S.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability for any direct or compensatory losses or damages caused to any person or entity, including but not limited to by any negligence (but excluding fraud, willful misconduct or any other type of liability that, for the avoidance of doubt, by law cannot be excluded) on the part of, or any contingency within or beyond the control of, MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising from or in connection with the information contained herein or the use of or inability to use any such information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY SUCH RATING OR OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY’S IN ANY FORM OR MANNER WHATSOEVER.

Moody’s Investors Service, Inc., a wholly-owned credit rating agency subsidiary of Moody’s Corporation (“MCO”), hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody’s Investors Service, Inc. have, prior to assignment of any rating, agreed to pay to Moody’s Investors Service, Inc. for appraisal and rating services rendered by it fees
MCO and MIS also maintain policies and procedures to address the independence of MIS’s ratings and rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities who hold ratings from MIS and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually at www.moodys.com under the heading “Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy.”

For Australia only: Any publication into Australia of this document is pursuant to the Australian Financial Services License of MOODY’S affiliate, Moody’s Investors Service Pty Limited ABN 61 003 399 657 AFSL 336969 and/or Moody’s Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to “wholesale clients” within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to MOODY’S that you are, or are accessing the document as a representative of, a “wholesale client” and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to “retail clients” within the meaning of section 761G of the Corporations Act 2001. MOODY’S credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail clients. It would be dangerous for “retail clients” to make any investment decision based on MOODY’S credit rating. If in doubt you should contact your financial or other professional adviser.

For Japan only: MOODY’S Japan K.K. (“MJKK”) is a wholly-owned credit rating agency subsidiary of MOODY’S Group Japan G.K., which is wholly-owned by Moody’s Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody’s SF Japan K.K. (“MSFJ”) is a wholly-owned credit rating agency subsidiary of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization (“NRSRO”). Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJKK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJKK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJKK or MSFJ (as applicable) have, prior to assignment of any rating, agreed to pay to MJKK or MSFJ (as applicable) for appraisal and rating services rendered by it fees ranging from JPY200,000 to approximately JPY350,000,000. MJKK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.